Exact Sciences Corporation
EXAS
株式のランク
#1156
Exact Sciences Corporation specializes in developing and distributing cancer... Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
株価
$104.91
最終同期: 2026-03-23
時価総額
$20.03B
変化（1日）
0.00%
変化（1年）
71.34%
国
US
取引 Exact Sciences Corporation (EXAS)
カテゴリー
Healthcare
Exact Sciences Corporation（EXAS）の営業利益率
October 2026 時点の営業利益率 TTM: -4.11%
Exact Sciences Corporation の最新の財務報告と株価によると、現在の営業利益率（TTM）は -4.11% です。2023 年末時点では -8.60% でした。
Exact Sciences Corporation の営業利益率の履歴（2000 から 2026）
各年末の営業利益率
| 年 | 営業利益率 | 変化 |
|---|---|---|
| 2026 (TTM) | -4.11% | -89.19% |
| 2024 | -38.01% | 341.98% |
| 2023 | -8.60% | -68.96% |
| 2022 | -27.71% | -41.39% |
| 2021 | -47.28% | 26.28% |
| 2020 | -37.44% | 40.33% |
| 2019 | -26.68% | -23.97% |
| 2018 | -35.09% | -21.11% |
| 2017 | -44.48% | -73.85% |
| 2016 | -170.08% | -57.83% |
| 2015 | -403.35% | -92.79% |
| 2014 | -5,591.71% | 395.54% |
| 2013 | -1,128.40% | -11.17% |
| 2012 | -1,270.32% | 83.48% |
| 2011 | -692.36% | 212.87% |
| 2010 | -221.29% | 14.34% |
| 2009 | -193.53% | -116.82% |
| 2008 | 1,150.29% | -362.79% |
| 2007 | -437.72% | 46.76% |
| 2006 | -298.25% | -18.92% |
| 2005 | -367.86% | -5.42% |
| 2004 | -388.96% | -60.87% |
| 2003 | -994.07% | -71.09% |
| 2002 | -3,438.68% | -93.31% |
| 2001 | -51,406.44% | 0.00% |
| 2000 | 0.00% | 0.00% |
同業他社の営業利益率
| 企業 | 営業利益率 | 営業利益率の差 | 国 |
|---|---|---|---|
| 17.97% | -104.37% |
US
|
|
| 20.42% | -104.97% |
US
|
|
| -10.70% | -97.40% |
US
|
|
| 0.00% | - |
CN
|
|
| 22.23% | -105.41% |
US
|
企業の営業利益率とは？
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。